Synergy Pharmaceuticals Inc (SGYP) 5.92 $SGYP
Synergy Pharma reports 3Q loss
Automated Insights - Mon Nov 09, 7:13AM CST
NEW YORK (AP) _ Synergy Pharmaceuticals Inc. (SGYP) on Monday reported a loss of $26 million in its third quarter.
SGYP: 5.92 (+0.03)
Synergy Pharmaceuticals Reports Third Quarter 2015 Financial Results and Business Update
Business Wire - Mon Nov 09, 7:00AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three and nine months ended September 30, 2015.
SGYP: 5.92 (+0.03)
Should You Buy Synergy Pharmaceuticals (SGYP) Ahead of Earnings?
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 7:58AM CST
Synergy Pharmaceuticals is seeing favorable earnings estimate revision activity as of late and may be poised to beat at earnings season
SGYP: 5.92 (+0.03)
3 Biotech Stocks to Buy in November
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Nov 01, 12:20PM CST
Image Source TBIT via pixabay Well, that was fast. A month ago it seemed like biotech stocks couldn't do anything right. Shares of the iShares Nasdaq Biotechnology ETF , which holds a huge collection of biotech stocks, were pummeled over fears...
SGYP: 5.92 (+0.03), IRWD: 11.87 (+0.43), ALXN: 166.44 (+0.31), IBB: 323.64 (+3.53), EXEL: 5.40 (-0.01)
5 Stocks Under $10 Set to Soar Higher
at The Street - Thu Oct 29, 9:11AM CDT
These under-$10 stocks look poised to break out and trade higher from current levels.
SGYP: 5.92 (+0.03), GBSN: 0.06 (unch), HLIT: 5.16 (-0.25), LEI: 2.54 (+0.11), CALA: 7.02 (-0.10), MPO: 3.74 (+0.10), FSNN: 2.18 (-0.05), LBIO: 6.80 (+0.01), GNCA: 5.84 (+0.11)
3 Biotech Long Shots That Could Be Worth Betting On
Todd Campbell, The Motley Fool - Motley Fool - Sun Oct 18, 7:02AM CDT
Source: Flickr user stockmonkeys.com. Investing in clinical-stage biotech stocks is incredibly risky, because any number of things can derail even the most promising therapy in human trials. Historically, 90% of drugs entering the clinic end up...
SGYP: 5.92 (+0.03), PTLA: 48.96 (-0.43), IRWD: 11.87 (+0.43), OPHT: 54.38 (+1.10)
BUYINS.NET: SGYP SqueezeTrigger Price is $5.79. There is $128,766,918 That Short Sellers Still Need To Cover.
M2 - Fri Oct 02, 12:12PM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Synergy Pharmaceuticals Inc (NASDAQ:SGYP) in real time and just received an alert that SGYP is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 22124900 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $5.79. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
SGYP: 5.92 (+0.03)
Scanning Active Equities from Diverse Sectors - Synergy Pharmaceuticals, Cemex, Standard Pacific, Rite Aid and Sirius XM
PR Newswire - Wed Sep 30, 11:52AM CDT
ACI Association has initiated research coverage on the following equities: Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP), Cemex S.A.B. de C.V. (NYSE: CX), Standard Pacific Corp (NYSE: SPF), Rite Aid Corporation (NYSE: RAD), and Sirius XM Holdings Inc. (NASDAQ: SIRI). On Tuesday, September 29, 2015, Nasdaq ended at 4,517.32, down 0.59%, Dow Jones advanced 0.30% to finish the day at 16,049.13, and the S&P closed at 1,884.09, up 0.12%. Register for your complimentary reports at the links given below.
SGYP: 5.92 (+0.03), CX: 5.54 (-0.34), SPF: 8.00 (+0.05), SIRI: 4.08 (-0.03), RAD: 7.60 (-0.08)
Herpes Zoster (Shingles) Global Clinical Trials Review, H1, 2015
M2 - Thu Sep 24, 10:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pbnk43/herpes_zoster) has announced the addition of the "Herpes Zoster (Shingles) Global Clinical Trials Review, H1, 2015" report to their offering. This clinical trial report, Herpes Zoster (Shingles) Global Clinical Trials Review, H1, 2015" provides an overview of Herpes Zoster (Shingles) clinical trials scenario. This report provides top line data relating to the clinical trials on Herpes Zoster (Shingles). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Reasons to Buy - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned - Ajanta Pharma - Astellas Pharma - Boehringer Ingelheim - GlaxoSmithKline - Hammersmith Medicines Research - Maruho - Merck & Co. - NeurogesX - Pfizer - Synergy Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/pb...pes_zoster
SGYP: 5.92 (+0.03), MRK: 53.03 (unch), GSK: 39.87 (-0.18)
Global Opioid-Induced Constipation (OIC) Pipeline Review 2015 - 7 Companies & 9 Drug Profiles
M2 - Wed Sep 23, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bc35rh/opioidinduced) has announced the addition of the "Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Opioid-Induced Constipation (OIC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opioid-Induced Constipation (OIC) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca Plc - Cosmo Pharmaceuticals S.p.A - Ironwood Pharmaceuticals, Inc. - Shionogi & Co., Ltd. - Sucampo Pharmaceuticals, Inc. - Synergy Pharmaceuticals, Inc. - Valeant Pharmaceuticals International, Inc. Drug Profiles - (axelopran sulfate oxycodone hydrochloride) - axelopran sulfate - dolcanatide - linaclotide - lubiprostone - methylnaltrexone bromide - naldemedine - naloxegol oxalate - naloxone hydrochloride For more information visit http://www.researchandmarkets.com/research/bc...oidinduced
SGYP: 5.92 (+0.03), IRWD: 11.87 (+0.43), AZN: 31.29 (+0.44), SCMP: 17.28 (-0.38), VRX.TO: 100.53 (+2.39)
7 Health Care Stocks John Paulson Is Betting On in 2015
at The Street - Tue Sep 15, 10:16AM CDT
When it comes to investing in health care, hedge fund pro John Paulson knows his stuff.
SGYP: 5.92 (+0.03), AGN: 299.63 (-0.41), PMC: 34.35 (+0.35), PRGO: 146.90 (-9.65), VRX: 75.41 (+1.64), SHPG: 203.58 (-2.36), AMGN: 151.55 (+0.57), MYL: 48.78 (+5.58), ABBV: 59.86 (-0.37), TEVA: 58.01 (-0.32), GRFS: 35.42 (-0.07), SURG: 6.69 (+0.09)
Synergy Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
Business Wire - Wed Sep 09, 5:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that its Chairman and Chief Executive Officer, Gary S. Jacob, Ph.D., will present a corporate update at the Morgan Stanley Global Healthcare Conference on Friday, September 18th, 2015 at 9:20 a.m. Eastern Time at the Grand Hyatt New York.
SGYP: 5.92 (+0.03), MS: 33.93 (-0.30)
Global Constipation Pipeline Review 2015 - 16 Companies & 18 Drug Profiles
M2 - Tue Sep 08, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b5h9s9/constipation) has announced the addition of the "Constipation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Constipation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Constipation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Ardelyx, Inc. - Astellas Pharma Inc. - Braintree Laboratories, Inc. - Daiichi Sankyo Company, Limited - Dong-A Socio Group - Ironwood Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - RaQualia Pharma Inc. - Rhythm Pharmaceuticals - Sanwa Kagaku Kenkyusho Co., Ltd. - Shire Plc - SK Biopharmaceuticals Co., Ltd. - Sucampo Pharmaceuticals, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synergy Pharmaceuticals, Inc. Drug Profiles - ASP-7663 - BLI-400 - DA-6886 - DS-3801 - DSP-6952 - elobixibat - KWA-0711 - linaclotide - lubiprostone - plecanatide - prucalopride succinate - relamorelin - relenopride hydrochloride - RQ-00000010 - SK-1202 - Small Molecule to Activate 5-HT1 Receptor for Constipation and Dyspepsia - tenapanor hydrochloride - Transilon For more information visit http://www.researchandmarkets.com/research/b5...nstipation
SGYP: 5.92 (+0.03), IRWD: 11.87 (+0.43), SHPG: 203.58 (-2.36), SCMP: 17.28 (-0.38)
'Mad Money' Lightning Round: Buy, Buy, Buy Constellation Brands
at The Street - Tue Aug 25, 5:00AM CDT
Cramer urges caution on Sysco, thinks Icahn Enterprises is ok but isn't interested in Clarcor.
SGYP: 5.92 (+0.03), SYY: 39.97 (-0.25), STZ: 132.20 (-1.18), BEAV: 44.25 (-0.42), IEP: 71.72 (-1.18), CLC: 49.14 (-0.06)
Jim Cramer's 'Mad Money' Recap: Want to Profit From Market Panic? Keep Your Head
at The Street - Mon Aug 24, 7:31PM CDT
Never confuse the day-to-day stock market action to the overall health of the U.S. economy, Cramer says.
SGYP: 5.92 (+0.03), AMZN: 642.35 (-23.25), HD: 120.00 (-3.81), KR: 36.05 (-0.46), KMB: 117.32 (-0.37), SYY: 39.97 (-0.25), STZ: 132.20 (-1.18), CLC: 49.14 (-0.06), VTR: 49.68 (-0.31), PEP: 98.04 (-0.33), DRI: 54.34 (-0.79), NFLX: 103.65 (-5.27), W: 36.52 (-2.39), BEAV: 44.25 (-0.42), GOOGL: 740.07 (-16.46), IEP: 71.72 (-1.18), VZ: 44.23 (-0.60), AAPL: 112.34 (-3.38), GIS: 55.81 (-0.39)
10 Stocks Billionaire John Paulson Is Buying in 2015
at The Street - Mon Aug 24, 11:07AM CDT
Here's a closer look at 10 stocks Paulson & Co. bought in the most recently reported quarter.
WWAV: 40.56 (-0.93), SGYP: 5.92 (+0.03), AGN: 299.63 (-0.41), PMC: 34.35 (+0.35), VRX: 75.41 (+1.64), BRCM: 51.38 (-0.26), SHPG: 203.58 (-2.36), MYL: 48.78 (+5.58), TEVA: 58.01 (-0.32), SYMX: 0.84 (-0.15), HOT: 74.99 (-1.04)
Synergy Pharmaceuticals Reports Second Quarter and First Half 2015 Financial Results and Business Update
Business Wire - Mon Aug 10, 3:30PM CDT
--Company on-track for first NDA filing with plecanatide for CIC in January 2016
SGYP: 5.92 (+0.03)
Irritable Bowel Syndrome - Pipeline Review, H1 2015
M2 - Thu Aug 06, 3:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w64m23/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - A. Menarini Industrie Farmaceutiche Riunite - Actavis - Alba Therapeutics - Alfa Wassermann - Ardelyx - Astellas Pharma - Dong-A Socio - GIcare Pharma - Hanmi Pharmaceuticals - ImmusanT - Ironwood Pharmaceuticals - Juno Therapeutics - Ono Pharmaceutical - Protagonist Therapeutics - RaQualia Pharma - SK Biopharmaceuticals - SK Chemicals - Sumitomo Dainippon Pharma - Synergy Pharmaceuticals - Synthetic Biologics - Takeda Pharmaceutical - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/w6...able_bowel
SGYP: 5.92 (+0.03), SYN: 2.25 (unch), IRWD: 11.87 (+0.43), JUNO: 50.00 (+0.11)
Synergy Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
Business Wire - Tue Aug 04, 5:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that its Chairman and Chief Executive Officer, Gary S. Jacob, Ph.D., will present a corporate update at the Canaccord Genuity 35th Annual Growth Conference on Thursday, August 13th, 2015 at 11:30 a.m. Eastern Time at the InterContinental in Boston, Massachusetts.
SGYP: 5.92 (+0.03)
Synergy Pharma reports 3Q loss
Automated Insights - Mon Nov 09, 7:13AM CST
NEW YORK (AP) _ Synergy Pharmaceuticals Inc. (SGYP) on Monday reported a loss of $26 million in its third quarter.
SGYP: 5.92 (+0.03)
Synergy Pharmaceuticals Reports Third Quarter 2015 Financial Results and Business Update
Business Wire - Mon Nov 09, 7:00AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three and nine months ended September 30, 2015.
SGYP: 5.92 (+0.03)
Should You Buy Synergy Pharmaceuticals (SGYP) Ahead of Earnings?
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 7:58AM CST
Synergy Pharmaceuticals is seeing favorable earnings estimate revision activity as of late and may be poised to beat at earnings season
SGYP: 5.92 (+0.03)
3 Biotech Stocks to Buy in November
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Nov 01, 12:20PM CST
Image Source TBIT via pixabay Well, that was fast. A month ago it seemed like biotech stocks couldn't do anything right. Shares of the iShares Nasdaq Biotechnology ETF , which holds a huge collection of biotech stocks, were pummeled over fears...
SGYP: 5.92 (+0.03), IRWD: 11.87 (+0.43), ALXN: 166.44 (+0.31), IBB: 323.64 (+3.53), EXEL: 5.40 (-0.01)
5 Stocks Under $10 Set to Soar Higher
at The Street - Thu Oct 29, 9:11AM CDT
These under-$10 stocks look poised to break out and trade higher from current levels.
SGYP: 5.92 (+0.03), GBSN: 0.06 (unch), HLIT: 5.16 (-0.25), LEI: 2.54 (+0.11), CALA: 7.02 (-0.10), MPO: 3.74 (+0.10), FSNN: 2.18 (-0.05), LBIO: 6.80 (+0.01), GNCA: 5.84 (+0.11)
3 Biotech Long Shots That Could Be Worth Betting On
Todd Campbell, The Motley Fool - Motley Fool - Sun Oct 18, 7:02AM CDT
Source: Flickr user stockmonkeys.com. Investing in clinical-stage biotech stocks is incredibly risky, because any number of things can derail even the most promising therapy in human trials. Historically, 90% of drugs entering the clinic end up...
SGYP: 5.92 (+0.03), PTLA: 48.96 (-0.43), IRWD: 11.87 (+0.43), OPHT: 54.38 (+1.10)
BUYINS.NET: SGYP SqueezeTrigger Price is $5.79. There is $128,766,918 That Short Sellers Still Need To Cover.
M2 - Fri Oct 02, 12:12PM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Synergy Pharmaceuticals Inc (NASDAQ:SGYP) in real time and just received an alert that SGYP is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 22124900 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $5.79. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
SGYP: 5.92 (+0.03)
Scanning Active Equities from Diverse Sectors - Synergy Pharmaceuticals, Cemex, Standard Pacific, Rite Aid and Sirius XM
PR Newswire - Wed Sep 30, 11:52AM CDT
ACI Association has initiated research coverage on the following equities: Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP), Cemex S.A.B. de C.V. (NYSE: CX), Standard Pacific Corp (NYSE: SPF), Rite Aid Corporation (NYSE: RAD), and Sirius XM Holdings Inc. (NASDAQ: SIRI). On Tuesday, September 29, 2015, Nasdaq ended at 4,517.32, down 0.59%, Dow Jones advanced 0.30% to finish the day at 16,049.13, and the S&P closed at 1,884.09, up 0.12%. Register for your complimentary reports at the links given below.
SGYP: 5.92 (+0.03), CX: 5.54 (-0.34), SPF: 8.00 (+0.05), SIRI: 4.08 (-0.03), RAD: 7.60 (-0.08)
Herpes Zoster (Shingles) Global Clinical Trials Review, H1, 2015
M2 - Thu Sep 24, 10:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pbnk43/herpes_zoster) has announced the addition of the "Herpes Zoster (Shingles) Global Clinical Trials Review, H1, 2015" report to their offering. This clinical trial report, Herpes Zoster (Shingles) Global Clinical Trials Review, H1, 2015" provides an overview of Herpes Zoster (Shingles) clinical trials scenario. This report provides top line data relating to the clinical trials on Herpes Zoster (Shingles). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Reasons to Buy - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned - Ajanta Pharma - Astellas Pharma - Boehringer Ingelheim - GlaxoSmithKline - Hammersmith Medicines Research - Maruho - Merck & Co. - NeurogesX - Pfizer - Synergy Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/pb...pes_zoster
SGYP: 5.92 (+0.03), MRK: 53.03 (unch), GSK: 39.87 (-0.18)
Global Opioid-Induced Constipation (OIC) Pipeline Review 2015 - 7 Companies & 9 Drug Profiles
M2 - Wed Sep 23, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bc35rh/opioidinduced) has announced the addition of the "Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Opioid-Induced Constipation (OIC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opioid-Induced Constipation (OIC) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca Plc - Cosmo Pharmaceuticals S.p.A - Ironwood Pharmaceuticals, Inc. - Shionogi & Co., Ltd. - Sucampo Pharmaceuticals, Inc. - Synergy Pharmaceuticals, Inc. - Valeant Pharmaceuticals International, Inc. Drug Profiles - (axelopran sulfate oxycodone hydrochloride) - axelopran sulfate - dolcanatide - linaclotide - lubiprostone - methylnaltrexone bromide - naldemedine - naloxegol oxalate - naloxone hydrochloride For more information visit http://www.researchandmarkets.com/research/bc...oidinduced
SGYP: 5.92 (+0.03), IRWD: 11.87 (+0.43), AZN: 31.29 (+0.44), SCMP: 17.28 (-0.38), VRX.TO: 100.53 (+2.39)
7 Health Care Stocks John Paulson Is Betting On in 2015
at The Street - Tue Sep 15, 10:16AM CDT
When it comes to investing in health care, hedge fund pro John Paulson knows his stuff.
SGYP: 5.92 (+0.03), AGN: 299.63 (-0.41), PMC: 34.35 (+0.35), PRGO: 146.90 (-9.65), VRX: 75.41 (+1.64), SHPG: 203.58 (-2.36), AMGN: 151.55 (+0.57), MYL: 48.78 (+5.58), ABBV: 59.86 (-0.37), TEVA: 58.01 (-0.32), GRFS: 35.42 (-0.07), SURG: 6.69 (+0.09)
Synergy Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
Business Wire - Wed Sep 09, 5:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that its Chairman and Chief Executive Officer, Gary S. Jacob, Ph.D., will present a corporate update at the Morgan Stanley Global Healthcare Conference on Friday, September 18th, 2015 at 9:20 a.m. Eastern Time at the Grand Hyatt New York.
SGYP: 5.92 (+0.03), MS: 33.93 (-0.30)
Global Constipation Pipeline Review 2015 - 16 Companies & 18 Drug Profiles
M2 - Tue Sep 08, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b5h9s9/constipation) has announced the addition of the "Constipation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Constipation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Constipation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Ardelyx, Inc. - Astellas Pharma Inc. - Braintree Laboratories, Inc. - Daiichi Sankyo Company, Limited - Dong-A Socio Group - Ironwood Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - RaQualia Pharma Inc. - Rhythm Pharmaceuticals - Sanwa Kagaku Kenkyusho Co., Ltd. - Shire Plc - SK Biopharmaceuticals Co., Ltd. - Sucampo Pharmaceuticals, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synergy Pharmaceuticals, Inc. Drug Profiles - ASP-7663 - BLI-400 - DA-6886 - DS-3801 - DSP-6952 - elobixibat - KWA-0711 - linaclotide - lubiprostone - plecanatide - prucalopride succinate - relamorelin - relenopride hydrochloride - RQ-00000010 - SK-1202 - Small Molecule to Activate 5-HT1 Receptor for Constipation and Dyspepsia - tenapanor hydrochloride - Transilon For more information visit http://www.researchandmarkets.com/research/b5...nstipation
SGYP: 5.92 (+0.03), IRWD: 11.87 (+0.43), SHPG: 203.58 (-2.36), SCMP: 17.28 (-0.38)
'Mad Money' Lightning Round: Buy, Buy, Buy Constellation Brands
at The Street - Tue Aug 25, 5:00AM CDT
Cramer urges caution on Sysco, thinks Icahn Enterprises is ok but isn't interested in Clarcor.
SGYP: 5.92 (+0.03), SYY: 39.97 (-0.25), STZ: 132.20 (-1.18), BEAV: 44.25 (-0.42), IEP: 71.72 (-1.18), CLC: 49.14 (-0.06)
Jim Cramer's 'Mad Money' Recap: Want to Profit From Market Panic? Keep Your Head
at The Street - Mon Aug 24, 7:31PM CDT
Never confuse the day-to-day stock market action to the overall health of the U.S. economy, Cramer says.
SGYP: 5.92 (+0.03), AMZN: 642.35 (-23.25), HD: 120.00 (-3.81), KR: 36.05 (-0.46), KMB: 117.32 (-0.37), SYY: 39.97 (-0.25), STZ: 132.20 (-1.18), CLC: 49.14 (-0.06), VTR: 49.68 (-0.31), PEP: 98.04 (-0.33), DRI: 54.34 (-0.79), NFLX: 103.65 (-5.27), W: 36.52 (-2.39), BEAV: 44.25 (-0.42), GOOGL: 740.07 (-16.46), IEP: 71.72 (-1.18), VZ: 44.23 (-0.60), AAPL: 112.34 (-3.38), GIS: 55.81 (-0.39)
10 Stocks Billionaire John Paulson Is Buying in 2015
at The Street - Mon Aug 24, 11:07AM CDT
Here's a closer look at 10 stocks Paulson & Co. bought in the most recently reported quarter.
WWAV: 40.56 (-0.93), SGYP: 5.92 (+0.03), AGN: 299.63 (-0.41), PMC: 34.35 (+0.35), VRX: 75.41 (+1.64), BRCM: 51.38 (-0.26), SHPG: 203.58 (-2.36), MYL: 48.78 (+5.58), TEVA: 58.01 (-0.32), SYMX: 0.84 (-0.15), HOT: 74.99 (-1.04)
Synergy Pharmaceuticals Reports Second Quarter and First Half 2015 Financial Results and Business Update
Business Wire - Mon Aug 10, 3:30PM CDT
--Company on-track for first NDA filing with plecanatide for CIC in January 2016
SGYP: 5.92 (+0.03)
Irritable Bowel Syndrome - Pipeline Review, H1 2015
M2 - Thu Aug 06, 3:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w64m23/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - A. Menarini Industrie Farmaceutiche Riunite - Actavis - Alba Therapeutics - Alfa Wassermann - Ardelyx - Astellas Pharma - Dong-A Socio - GIcare Pharma - Hanmi Pharmaceuticals - ImmusanT - Ironwood Pharmaceuticals - Juno Therapeutics - Ono Pharmaceutical - Protagonist Therapeutics - RaQualia Pharma - SK Biopharmaceuticals - SK Chemicals - Sumitomo Dainippon Pharma - Synergy Pharmaceuticals - Synthetic Biologics - Takeda Pharmaceutical - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/w6...able_bowel
SGYP: 5.92 (+0.03), SYN: 2.25 (unch), IRWD: 11.87 (+0.43), JUNO: 50.00 (+0.11)
Synergy Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
Business Wire - Tue Aug 04, 5:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that its Chairman and Chief Executive Officer, Gary S. Jacob, Ph.D., will present a corporate update at the Canaccord Genuity 35th Annual Growth Conference on Thursday, August 13th, 2015 at 11:30 a.m. Eastern Time at the InterContinental in Boston, Massachusetts.
SGYP: 5.92 (+0.03)
